In this study, researchers aimed to determine whether younger BRCA1/2 carriers who undergo oophorectomy can receive menopausal hormone therapy without increasing their risk of breast cancer.

In a study that involved more than 31,000 women who are carriers of disease-associated mutations in the BRCA1 or BRCA2 genes, researchers identified mutations that were associated with significantly ...

Deescalated nab-paclitaxel plus carboplatin showed higher efficacy than nab-paclitaxel plus gemcitabine in early-stage TNBC patients. BRCA1/2 mutation carriers exhibited a more pronounced pathologic ...

More and more studies show that men face risks of cancer from BRCA1 and BRCA2 genetic mutations that are most often associated with breast and ovarian cancers in women. According to a July 25 JAMA ...

Breast-conserving therapy for BRCA1/2 mutation carriers has higher risks of future breast cancers than the general population, but most patients avoid another cancer event, and many remain bilateral ...

Should screening for BRCA1/2 mutations be expanded to all women diagnosed with breast cancer? This is the recommendation put forth in recent guidelines from the American Society of Clinical Oncology ...

An affordable new BRCA gene test has hit the market, but who should take it? — -- A new genetic testing kit that hits the market today is the most affordable, and arguably one of the simplest, ...